Two long‐term phase 3 studies of enarodustat (JTZ‐951) in Japanese anemic patients with chronic kidney disease not on dialysis or on maintenance hemodialysis: SYMPHONY ND‐Long and HD‐Long studies

Enarodustat (JTZ‐951) is an oral hypoxia‐inducible factor prolyl hydroxylase inhibitor developed for treating anemia in chronic kidney disease. Two open‐label, uncontrolled phase 3 studies evaluated the 52‐week safety and efficacy of enarodustat in Japanese anemic patients with chronic kidney diseas...

Descripción completa

Detalles Bibliográficos
Autores principales: Akizawa, Tadao, Nangaku, Masaomi, Yamaguchi, Takuhiro, Koretomo, Ryosuke, Maeda, Kazuo, Yamada, Osamu, Hirakata, Hideki
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley & Sons Australia, Ltd 2021
Materias:
Original Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9290460/
https://www.ncbi.nlm.nih.gov/pubmed/34390314
http://dx.doi.org/10.1111/1744-9987.13724

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9290460/
https://www.ncbi.nlm.nih.gov/pubmed/34390314
http://dx.doi.org/10.1111/1744-9987.13724

Ejemplares similares